Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB9OGI)

Drug Name

N-Methyl-N-Propargyl-1(R)-Aminoindan Drug Info

Synonyms

124192-87-6; N-METHYL-N-PROPARGYL-1(R)-AMINOINDAN; (R)-N-Methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (R)-2,3-Dihydro-N-methyl-N-2-propynyl-1H-inden-1-amine; (R)-N-Methyl-N-(2-propynyl)-2,3-dihydroinden-1-amine; UNII-1Y7XS87IZR; 1Y7XS87IZR; CHEMBL436947; (1R)-N-methyl-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; N-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YL]-N-METHYL-N-PROP-2-YNYLAMINE; R-MPAI; N-Methyl-N-2-propynyl-1-indanamine, (R)-; AC1NRD15; 1H-Inden-1-amine,2,3-dihydro-N-methyl-N-2-propyn-1-yl-, (1R)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5289295
CAS Number: CAS 124192-87-6
TTD Drug ID: DMB9OGI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[2]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[3]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[4]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[5]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[6]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[7]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[8]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[9]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[10]
Budipine	DMODHQI	Migraine	8A80	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
3	Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
4	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
6	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
8	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
9	Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
11	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.